Why Allakos Stock Is on Fire Today
Specifically, the clinical-stage immunomodulatory receptor specialist's stock price was up by a healthy 24.7%, on heavy volume, as of 1:15 p.m. ET Wednesday afternoon. After all, Allakos stock has been a prime short-seller target ever since the biotech's late-stage monoclonal antibody lirentelimab missed the goalpost as a treatment for eosinophilic gastrointestinal diseases late last year. This small-cap biotech is the epitome of a high-risk, high-reward play.